AHP Dimetapp, Robitussin PPA Withdrawals Lead To $80 Mil. Charge In 2000
This article was originally published in The Tan Sheet
Executive Summary
American Home Products recorded an $80 mil. charge in the fourth quarter due to its removal of eight Dimetapp products and one Robitussin item in response to data linking phenylpropanolamine with hemorrhagic stroke, the company said Jan. 25.
You may also be interested in...
Dimetapp Line Extensions Filling Void Of PPA Product Withdrawals
Two new Whitehall-Robins' Dimetapp formulations are debuting at the height of the cough/cold season, replacing phenylpropanolamine-containing remedies withdrawn from the market in November.
Whitehall ChapStick Overnight TV, Print Ads Break
Whitehall-Robins Healthcare's ChapStick Overnight Lip Treatment TV and print ad campaign, launched in November, carries the tag, "For smoother, softer lips overnight."
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.